ITLN1

Across TCGA pan-cancer cohorts, ITLN1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ITLN1 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITLN1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ITLN1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ITLN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.852	0.657	<.001	77	view →
LUAD	OS	Quartile	II,III,IV	0.387	1.000	.005	28	view →
LSCC	OS	Median	III,IV	0.925	0.789	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ITLN1–PDAC (DFS)

Open the PDAC breakdown →